These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 19049657)

  • 1. Population approaches in paediatrics.
    Chatelut E
    Fundam Clin Pharmacol; 2008 Dec; 22(6):575-8. PubMed ID: 19049657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling.
    Ince I; de Wildt SN; Tibboel D; Danhof M; Knibbe CA
    Drug Discov Today; 2009 Mar; 14(5-6):316-20. PubMed ID: 19059496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of drugs in pediatrics using K-PD models: perspectives.
    Tod M
    Fundam Clin Pharmacol; 2008 Dec; 22(6):589-94. PubMed ID: 19049659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can positron emission tomography facilitate paediatric drug development?
    Zimmer L
    Fundam Clin Pharmacol; 2008 Dec; 22(6):595-8. PubMed ID: 19049660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of pharmacokinetic-pharmacodynamic relationships in drug development].
    Bellissant E; Courcier-Duplantier S; Blin O;
    Therapie; 2002; 57(4):347-57. PubMed ID: 12422555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of modelling and simulation into the development of intravenous busulfan in paediatrics: an industrial experience.
    Nguyen L
    Fundam Clin Pharmacol; 2008 Dec; 22(6):599-604. PubMed ID: 19049661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic predictions in children by using the physiologically based pharmacokinetic modelling.
    Bouzom F; Walther B
    Fundam Clin Pharmacol; 2008 Dec; 22(6):579-87. PubMed ID: 19049658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modelling approaches to dose estimation in children.
    Johnson TN
    Br J Clin Pharmacol; 2005 Jun; 59(6):663-9. PubMed ID: 15948929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotic dosing in children in Europe: can we grade the evidence from pharmacokinetic/pharmacodynamic studies - and when is enough data enough?
    Barker CI; Standing JF; Turner MA; McElnay JC; Sharland M
    Curr Opin Infect Dis; 2012 Jun; 25(3):235-42. PubMed ID: 22517604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PK/PD modelling and simulations: utility in drug development.
    Rajman I
    Drug Discov Today; 2008 Apr; 13(7-8):341-6. PubMed ID: 18405847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microdialysis for pharmacokinetic-pharmacodynamic studies.
    Yu W; Cheng Q; Feng J; Li F
    Pharmazie; 2007 Dec; 62(12):883-91. PubMed ID: 18214337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current concepts in pharmacokinetics and their implications for clinical medicine.
    Müller M; Müller-Zellenberg U; Hochhaus G; Derendorf H
    Wien Klin Wochenschr; 2001 Aug; 113(15-16):566-72. PubMed ID: 11571833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tools to define the relevance of PK/PD parameters to the efficacy, toxicity and emergence of resistance of antimicrobials.
    Hickey E
    Curr Opin Drug Discov Devel; 2007 Jan; 10(1):49-52. PubMed ID: 17265741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of modeling and simulation in pediatric investigation plans.
    Manolis E; Osman TE; Herold R; Koenig F; Tomasi P; Vamvakas S; Saint Raymond A
    Paediatr Anaesth; 2011 Mar; 21(3):214-21. PubMed ID: 21244569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.
    Thai HT; Mazuir F; Cartot-Cotton S; Veyrat-Follet C
    Br J Clin Pharmacol; 2015 Sep; 80(3):534-47. PubMed ID: 26095234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trial simulations in paediatric oncology: A feasibility study from the Innovative Therapies for Children with Cancer Consortium.
    Janssen JM; Zwaan CM; Schellens JHM; Beijnen JH; Huitema ADR
    Eur J Cancer; 2017 Nov; 85():78-85. PubMed ID: 28892776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
    Danhof M; de Lange EC; Della Pasqua OE; Ploeger BA; Voskuyl RA
    Trends Pharmacol Sci; 2008 Apr; 29(4):186-91. PubMed ID: 18353445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacodynamic and pharmacokinetic modeling via mixed effects.
    Piotrovsky VK
    Curr Opin Drug Discov Devel; 2000 May; 3(3):314-30. PubMed ID: 19649865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug development perspective on pharmacokinetic studies of new drugs in patients with renal impairment.
    Lalonde RL; Wagner JA
    Clin Pharmacol Ther; 2009 Nov; 86(5):557-61. PubMed ID: 19776736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electronic monitoring of variation in drug intakes can reduce bias and improve precision in pharmacokinetic/pharmacodynamic population studies.
    Vrijens B; Goetghebeur E
    Stat Med; 2004 Feb; 23(4):531-44. PubMed ID: 14755387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.